Emmaus Life Sciences, Inc.

pharmaceutical-grade L-glutamine (PGLG)

diverticulosis

Phase 1 trial initiated enrolling 10 patients at multiple sites

Enanta Pharmaceuticals, Inc.

EDP-514

hepatitis B virus (HBV)

Phase 1a/1b trial initiated enrolling 98 subjects

Neurovive Pharmaceutical AB

KL1333

mitochondrial disease

Phase 1a/1b trial initiated enrolling healthy subjects in the UK after successful completion of the first stage of enrollment

Auris Medical
Holding Ltd.

AM-201

antipsychotic-induced weight gain and somnolence

Phase 1b trial initiated enrolling healthy volunteer subjects in Europe

4D pharma plc

MRx-4DP0004

asthma

Phase 1/2 trial initiated enrolling 90 subjects not adequately controlled on their current inhaler maintenance therapy

Vedanta Biosciences

VE416

peanut allergy

Phase 1b/2 trial initiated enrolling 40 subjects 12 years of age and older at MassGeneral Hospital for Children in Boston

ActoBio Therapeutics, Inc.

AG019

early-onset type 1 diabetes (T1D)

Phase 1b/2a trial initiated enrolling subjects 12 to 17 years of age

ActoBio Therapeutics, Inc.

AG019 combined with teplizumab (PRV-031)

early-onset type 1 diabetes (T1D)

Phase 1b/2a trial initiated enrolling adult subjects

Biohaven Pharmaceutical Holding Company Ltd.

rimegepant

treatment refractory trigeminal neuralgia

Phase 2 trial initiated enrolling subjects at Johns Hopkins Medical Center

GlaxoSmithKline

otilimab

moderate to severe rheumatoid arthritis (RA)

Phase 3 trial initiated

BiondVax Pharmaceuticals Ltd.

M-001

influenza

Phase 3 trial initiated

Alexion Pharmaceuticals, Inc.

SOLIRIS (eculizumab)

neuromyelitis optica spectrum disorder (NMOSD) in adult subjects who are anti-aquaporin-4 (AQP4) antibody positive

Approval granted by the FDA

Janssen

DARZALEX (daratumumab) in combination with lenalidomide and dexamethasone (Rd)

subjects with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant (ASCT)

Approval granted by the FDA

Pfizer

ZIRABEV (bevacizumab-bvzr)

metastatic colorectal cancer; unresectable, locally advanced, recurrent or metastatic non-squamous non-small cell lung cancer (NSCLC); recurrent glioblastoma; metastatic renal cell carcinoma (RCC); and persistent, recurrent or metastatic cervical cancer

Approval granted by the FDA

Janssen

Genmab

Darzalex (daratumumab) in combination with lenalidomide and dexamethasone as a first-line treatment

multiple myeloma subjects who are ineligible for autologous stem cell transplant (ASCT)

Approval granted by the FDA

Alexion Pharmaceuticals

Soliris (eculizumab)

neuromyelitis optica spectrum disorder (NMOSD) in adult subjects that express a specific biomarker

Approval granted by the FDA

Teva Pharmaceuticals

1% Sodium Hyaluronate

osteoarthritis (OA) of the knee in subjects who have failed to respond adequately to conservative non-pharmacologic therapy and simple analgesics (e.g., acetaminophen)

Approval granted by the FDA

Retrophin

Thiola EC (tiopronin) 100 mg and 300 mg tablets

cystinuria

Approval granted by the FDA

Grifols

Xembify 20% subcutaneous immunoglobulin

primary immunodeficiencies

Approval granted by the FDA